New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
07:08 EDTINSYInsys backs Q2 revenue view of over $52M, consensus $52.77M
Insys Therapeutics reaffirmed its revenue guidance for Q2 ended June 30. Revenue from sales of Subsys is expected to exceed $52M for the quarter, as compared with $18.5M during 2Q13.
News For INSY From The Last 14 Days
Check below for free stories on INSY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
09:11 EDTINSYOn The Fly: Pre-market Movers
Subscribe for More Information
07:07 EDTINSYInsys Therapeutics receives FDA orphan drug designation for CBD
Insys Therapeutics announced that the FDA has granted orphan drug designation to its pharmaceutical cannabidiol, or CBD, for the treatment of glioblastoma multiforme, or GBM, the most common and most aggressive malignant primary brain tumor in humans. In addition to receiving orphan drug designation, Insys has recently entered into an exclusive licensing agreement with California Pacific Medical Center on behalf of its Research Institute, or CPMCRI, based in San Francisco to license CPMCRI's patent rights related to the usage of cannabinoids for the treatment of GBM.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use